A double-blind, randomized trial of 0.05 percent podofilox and placebo for the treatment of genital warts in women

Article Abstract:

The most common sexually transmitted viral disease in the United States is infection with the human papillomavirus (HPV), which causes the development of genital warts. The incidence of genital HPV infection has increased to epidemic proportions, and the need for medical services to manage genital HPV infection has become overwhelming. In addition, at least 12 of 66 HPV types may cause lower genital tract neoplasia, or new abnormal growths. A self-applicable treatment for genital condylomas, or warts, is needed. Podofilox, also known as podophyllotoxin, has been shown to be effective in treating condyloma acuminata, which are warts that develop in areas near the genital organs and anus, mainly in men. The effectiveness of podofilox was assessed in 72 women with external genital warts. Self-applicable preparations of 0.5 percent podofilox or inert placebo were applied twice daily for three days, followed by four days without treatment, for between two to four weeks. The number of warts and overall condition of the patients was assessed at 4, 6, and 10 weeks. Podofilox eliminated 74 percent of all warts, as compared with 18 percent of warts that resolved without treatment. The drug caused more improvement in overall condition than the placebo. Podofilox treatment was associated with few transient side effects, and no systemic effects. These findings suggest that self-applicable preparations of 0.5 percent podofilox are safe and effective in treating genital warts in women. (Consumer Summary produced by Reliance Medical Information, Inc.)

Papillomaviruses, Papillomavirus

---

Topical podofilox for the treatment of Condylomata acuminata in women

Article Abstract:

Condylomata acuminata, or genital warts, are caused by human papillomavirus (HPV). The incidence of HPV infection is so high that it may be the most common viral sexually transmitted disease. Some HPV infections are associated with subsequent genital cancers. Podophyllin, derived from the mandrake plant, is a mixture of compounds that have a caustic effect, and has been the most frequently used treatment for condylomata since the 1940s. A single active noncaustic compound, podofilox, has been isolated from the mixture. The safety and effectiveness of podofilox in self-treatment of genital warts were evaluated in 37 women. After 10 weeks of treatment with podofilox, the average number of warts decreased by 83 percent, with elimination of 72 percent of the genital warts. Half of the patients were completely free of warts after the 10-week treatment period. However, eight women who became wart-free subsequently developed new warts. Local side effects, such as pain, burning, inflammation, and erosion, were most severe during the first week of treatment. The results indicate that podofilox may be safely applied by patients and, with physician follow-up, provides an economic alternative to other forms of treatment for genital warts. (Consumer Summary produced by Reliance Medical Information, Inc.)

---

Once-daily valacyclovir to reduce the risk of transmission of genital heroes

Article Abstract:

The antiviral drug valacyclovir may reduce the risk of genital herpes transmission among couples by 50%, according to a study of 1,484 couples. One partner was infected with genital herpes and the other was not. Valacyclovir also reduced the secretion of the virus in genital fluids.

Prevention, Communicable diseases, Disease transmission, Herpes genitalis, Genital herpes, Valacyclovir

Similar abstracts:

• Abstracts: A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. part 2
• Abstracts: Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection
• Abstracts: Endotoxin increases the nephrotoxic potential of gentamicin and vancomycin plus gentamicin. Uptake and binding of liposomal 2',3'-dideoxycytidine by RAW 264.7 cells: a three-step process
• Abstracts: The fallacy of the screening interval for cervical smears. Colposcopic evaluation of human immunodeficiency virus-seropositive women
• Abstracts: Management of endometrial cancer with suspected cervical involvement. Primary invasive carcinoma of the vagina

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.